<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2097">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04568707</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200845</org_study_id>
    <nct_id>NCT04568707</nct_id>
  </id_info>
  <brief_title>Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES)</brief_title>
  <official_title>Evaluation of Biological Response to SARS-COV2 in Patients With Pre-existing Neurological Disease or With New Neurological Manifestations of COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Brain &amp; Spine Institute (ICM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with neurological or psychiatric symptoms or pre-existing disease will be sampled
      (blood for serum and DNA or saliva for DNA) at inclusion and at M6 (blood) and M12 (blood)
      depending on their pathology. Sampling will be done either at hospital if patient is on site
      for routine care or at home if no consultation is scheduled at hospital.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 15, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients</measure>
    <time_frame>12 months</time_frame>
    <description>dosage of seric markers (anti-SARS-CoV2 IgG) or genetic markers (genetic variants) observed during COVID 19 infection in patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum neurofilaments</measure>
    <time_frame>12 months</time_frame>
    <description>Neurodegenerative markers (e.g., neurofilaments) associated with a neurological or psychiatric manifestation of Covid-19 infection</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Covid19</condition>
  <condition>Neurologic Manifestations</condition>
  <condition>Psychiatric Manifestations</condition>
  <arm_group>
    <arm_group_label>Covid-19 infection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Covid-19 infection defined by a positive PCR or a typical chest scanner of Covid-19 infection or a positive serology or a typical clinical picture in a pandemic period</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>blood sample for serum (serology, biomarkers) and DNA</description>
    <arm_group_label>Covid-19 infection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        1. Age over 18 yo

          2. Patient having presented or presenting a Covid-19 infection defined by a positive PCR
             or a typical chest scanner of Covid-19 infection or a positive serology or a typical
             clinical picture in a pandemic period

          3. And patient with:

               1. a neurological or psychiatric manifestation de novo during or after the Covid-19
                  infection and/or

               2. either a chronic neurological or psychiatric pathology
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Céline LOUAPRE, MD</last_name>
    <phone>1 42 16 57 66</phone>
    <phone_ext>+33</phone_ext>
    <email>celine.louapre@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Christophe CORVOL, MD,PHD</last_name>
    <phone>1 42 16 57 66</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-christophe.corvol@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Céline LOUAPRE, MD</last_name>
      <phone>1 42 16 57 66</phone>
      <phone_ext>+33</phone_ext>
      <email>celine.louapre@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Céline LOUAPRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 29, 2020</study_first_posted>
  <last_update_submitted>September 28, 2020</last_update_submitted>
  <last_update_submitted_qc>September 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>neurological disease</keyword>
  <keyword>Multiple Sclerosis</keyword>
  <keyword>psychiatric disease</keyword>
  <keyword>biology,</keyword>
  <keyword>biocollection,</keyword>
  <keyword>biomarkers,</keyword>
  <keyword>DNA,</keyword>
  <keyword>Parkinson's Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Neurologic Manifestations</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

